LIVZON PHARMAC (Germany) Performance
| LP6 Stock | EUR 3.14 0.06 1.95% |
The company secures a Beta (Market Risk) of -0.36, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning LIVZON PHARMAC are expected to decrease at a much lower rate. During the bear market, LIVZON PHARMAC is likely to outperform the market. At this point, LIVZON PHARMAC GRP has a negative expected return of -0.0275%. Please make sure to verify LIVZON PHARMAC's kurtosis, rate of daily change, and the relationship between the skewness and daily balance of power , to decide if LIVZON PHARMAC GRP performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days LIVZON PHARMAC GRP has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, LIVZON PHARMAC is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Price Earnings Ratio | 11.1852 | |
| Dividend Yield | 0.0594 | |
| Payout Ratio | 0.6547 |
LIVZON |
LIVZON PHARMAC Relative Risk vs. Return Landscape
If you would invest 322.00 in LIVZON PHARMAC GRP on October 14, 2024 and sell it today you would lose (8.00) from holding LIVZON PHARMAC GRP or give up 2.48% of portfolio value over 90 days. LIVZON PHARMAC GRP is currently producing negative expected returns and takes up 1.6714% volatility of returns over 90 trading days. Put another way, 14% of traded stocks are less volatile than LIVZON, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
LIVZON PHARMAC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LIVZON PHARMAC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LIVZON PHARMAC GRP, and traders can use it to determine the average amount a LIVZON PHARMAC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0165
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LP6 |
Estimated Market Risk
| 1.67 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average LIVZON PHARMAC is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LIVZON PHARMAC by adding LIVZON PHARMAC to a well-diversified portfolio.
LIVZON PHARMAC Fundamentals Growth
LIVZON Stock prices reflect investors' perceptions of the future prospects and financial health of LIVZON PHARMAC, and LIVZON PHARMAC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LIVZON Stock performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0514 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.15 % | |||
| Shares Outstanding | 309.83 M | |||
| Price To Earning | 4.02 X | |||
| Revenue | 12.18 B | |||
| EBITDA | 2.3 B | |||
| Cash And Equivalents | 1.14 B | |||
| Cash Per Share | 1.58 X | |||
| Total Debt | 22.97 M | |||
| Debt To Equity | 1.30 % | |||
| Book Value Per Share | 14.37 X | |||
| Cash Flow From Operations | 192.47 M | |||
| Earnings Per Share | 0.27 X | |||
About LIVZON PHARMAC Performance
By analyzing LIVZON PHARMAC's fundamental ratios, stakeholders can gain valuable insights into LIVZON PHARMAC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if LIVZON PHARMAC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LIVZON PHARMAC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical products in the Peoples Republic of China. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China. Livzon Pharmaceutical operates under Drug Manufacturers - Specialty Generic classification in Germany and traded on Frankfurt Stock Exchange. It employs 6963 people.Things to note about LIVZON PHARMAC GRP performance evaluation
Checking the ongoing alerts about LIVZON PHARMAC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LIVZON PHARMAC GRP help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LIVZON PHARMAC GRP generated a negative expected return over the last 90 days | |
| About 53.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing LIVZON PHARMAC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LIVZON PHARMAC's stock is overvalued or undervalued compared to its peers.
- Examining LIVZON PHARMAC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LIVZON PHARMAC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of LIVZON PHARMAC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LIVZON PHARMAC's stock. These opinions can provide insight into LIVZON PHARMAC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for LIVZON Stock analysis
When running LIVZON PHARMAC's price analysis, check to measure LIVZON PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LIVZON PHARMAC is operating at the current time. Most of LIVZON PHARMAC's value examination focuses on studying past and present price action to predict the probability of LIVZON PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LIVZON PHARMAC's price. Additionally, you may evaluate how the addition of LIVZON PHARMAC to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets |